<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03188601</url>
  </required_header>
  <id_info>
    <org_study_id>0196-17-RMB</org_study_id>
    <secondary_id>A1373</secondary_id>
    <nct_id>NCT03188601</nct_id>
  </id_info>
  <brief_title>α1-antitrypsin (AAT) Levels and Functions in Allogeneic Bone Marrow Transplantation and Throughout Progression Into GVHD</brief_title>
  <acronym>AATGVHD-MARK</acronym>
  <official_title>Relative Inactivity of Alpha-1-antitrypsin After Bone Marrow Transplantation as a Dynamic Biomarker for GVHD and Prognosis: a Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Soroka University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Create a personalized time and context curve of patient circulating α1-antitrypsin (AAT)&#xD;
      levels and functions before hematopoietic stem cell transplantation and throughout&#xD;
      progression into GVHD.&#xD;
&#xD;
      PRIMARY ENDPOINT 1. Serum AAT levels and activity, before myeloablative preconditioning, as&#xD;
      well as on days (-3),0,7,14,28 from HSCT and every 21 days thereafter.&#xD;
&#xD;
      SECONDARY ENDPOINTS 1. Correlation between AAT patterns and:&#xD;
&#xD;
        -  Circulating immune cell activation profiles on day of ablation, 28 days from HSCT and&#xD;
           once GVHD is diagnosed.&#xD;
&#xD;
        -  Patient survival&#xD;
&#xD;
        -  Liver function tests&#xD;
&#xD;
        -  GVHD grade: skin manifestations, weight, GI and liver histopathology&#xD;
&#xD;
        -  Graft-versus-leukemia effect&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will focus on each individual patient from the early point of myeloablative&#xD;
      conditioning through HSCT and GVHD. The rationale for this individualized approach is to&#xD;
      account for the anticipated variability in patient age and primary disease, background&#xD;
      pathology and individual therapeutic course, considering the enormous heterogeneity of this&#xD;
      condition. To compensate for this limitation, we intend to create an individualized&#xD;
      algorithm, based on a novel dynamic biomarker, i.e., AAT functionality, individualized per&#xD;
      patient and placed on a timeline, with the aim of minimizing future occurrences of GVHD, and&#xD;
      by using readily available laboratory measurements. The study is designed around patient&#xD;
      sample collection, there is no change in standard of care, therefore there is no intervention&#xD;
      as well.&#xD;
&#xD;
      Three types of sample tubes will be collected per indicated time point:&#xD;
&#xD;
        -  Serum tube for protein levels and enzymatic activity assays.&#xD;
&#xD;
        -  EDTA tube for isolation of peripheral blood mononuclear cells (PBMCs), cells will be&#xD;
           stimulated and then analyzed by FACS and lysed for RT-PCR&#xD;
&#xD;
        -  EDTA tube for whole blood stimulation assay for further FACS analysis and cytokine&#xD;
           production measurement.&#xD;
&#xD;
      After donor and recipient informed consent forms were signed, a single blood sample should be&#xD;
      obtained from the donor on the day of transplant extraction. Time points for recipient's&#xD;
      samples include the day of myeloablation and again immediately prior to HSCT (set as day 0&#xD;
      and possibly -3 in MUDs). Serum and lysed blood samples will be collected on days 7, 14, 28,&#xD;
      and every 21 days thereafter, through the development and progression of GVHD (where&#xD;
      relevant). Blood samples for FACS will be collected by days 0 and 28. Sample collection is&#xD;
      planned to end within 1 year from HSCT, or two months after appearance of symptoms of GVHD,&#xD;
      or two months after a change is introduced in the immunosuppressive therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 27, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Number of patients progressing into acute or chronic GVHD</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Evaluation of patient circulating alpha-1-antitrypsin levels and enzymatic functions as a bio-marker for GVHD progression and grading</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between AAT pattern and survivability, response to immunosuppressive treatment. liver functions, immunocyte activities.</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Correlation between AAT patterns and:&#xD;
Circulating immune cell activation profiles on day of ablation, 28 days from HSCT and once GVHD is diagnosed.&#xD;
Patient survival&#xD;
Liver function tests&#xD;
GVHD grade: skin manifestations, weight, GI and liver histopathology&#xD;
Graft-versus-leukemia effect</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>GVHD</condition>
  <condition>Bone Marrow Transplant Failure</condition>
  <condition>Alpha 1-Antitrypsin</condition>
  <arm_group>
    <arm_group_label>Rambam</arm_group_label>
    <description>Approximately 40 patients in total.No intervention planned.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Soroka</arm_group_label>
    <description>Approximately 10 patients in total.No intervention planned.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tel Aviv Souraski</arm_group_label>
    <description>Approximately 40 patients in total.No intervention planned.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Jerusalem Hadassah</arm_group_label>
    <description>Approximately 50 patients in total. No intervention planned.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum samples and peripheral blood mononuclear cells' RNA extracts&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        In every medical center in which a bone marrow transplantation is performed, allogeneic&#xD;
        transplantation recipients will be recruited for the trial.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Candidates for allogeneic transplantation for the first time, scheduled to receive&#xD;
             HSCT from HLA-matched sibling or an unrelated matched donor&#xD;
&#xD;
          -  Signed informed consent by the donor(Healthy volunteers) and the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing immunosuppressive treatment prior to preparation for bone-marrow&#xD;
             transplantation.&#xD;
&#xD;
          -  Pregnant and disabled patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eli Lewis, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ben-Gurion University of the Negev</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah</name>
      <address>
        <city>Jerusalem</city>
        <state>Center</state>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center - Ichilov Hospital</name>
      <address>
        <city>Tel Aviv</city>
        <state>Center</state>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam MC</name>
      <address>
        <city>Haifa</city>
        <state>North</state>
        <zip>3525408</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Beer sheva</city>
        <state>South</state>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 13, 2017</study_first_submitted>
  <study_first_submitted_qc>June 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2017</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Graft vs Host Disease</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Protease Inhibitors</keyword>
  <keyword>Alpha 1-Antitrypsin</keyword>
  <keyword>Enzyme Inhibitors</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <keyword>Trypsin Inhibitors</keyword>
  <keyword>Serine Proteinase Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The clinical individual participant data will be further analyzed by other researchers after the study is completed.That is in order to combine this clinical data with other experiments' results. no</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

